VTRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Viatris Inc (VTRS) is not a compelling buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock's technical indicators show a bearish trend, and while there are positive catalysts such as analyst upgrades and cost-saving initiatives, the company's recent financial performance and hedge fund selling trends raise concerns. It is advisable to hold off on investing in this stock for now.
The stock is in a bearish trend with a negatively expanding MACD histogram (-0.289), RSI at 25.702 (neutral zone), and converging moving averages. The price is trading near its support level (S1: 14.281), with resistance levels at R1: 16.176 and R2: 16.761. The post-market price is $14.17, reflecting a slight increase of 0.07%, but the regular market saw a decline of -2.55%.
UBS raised the price target to $20, highlighting cost-saving initiatives and potential revenue growth.
Analysts have generally upgraded the stock, citing margin expansion, a growing product pipeline, and capital allocation improvements.
Dividend payment scheduled for March 18, 2026, which may attract income-focused investors.
Hedge funds are selling, with a 247.32% increase in selling activity over the last quarter.
The company's Q4 2025 financials show a net income drop of -34.15% YoY and a negative EPS of -0.3, indicating profitability concerns.
Technical indicators suggest a bearish trend, with no clear reversal signals.
In Q4 2025, revenue increased by 4.97% YoY to $3.7 billion, and gross margin improved slightly to 40.25%. However, net income dropped significantly by -34.15% YoY to -$340.1 million, and EPS fell by -30.23% YoY to -0.3, indicating declining profitability.
Analysts have a mixed-to-positive outlook on Viatris. UBS raised the price target to $20 and maintained a Buy rating, citing cost-saving initiatives and potential revenue growth. JPMorgan raised the price target to $16 but kept a Neutral rating. Other analysts, including Argus and Barclays, have upgraded the stock to Buy, citing attractive valuation, margin expansion, and a growing pipeline. However, the stock remains under pressure due to recent market performance and hedge fund selling trends.
